Endometrial surveillance of women on tamoxifen;Surveillance de l'endomètre des femmes sous tamoxifène

Gynecologie Obstetrique et Fertilite

Volumn 31, Issue 7-8, 2003, Pages 647-656

  Lhomme C ^a   Pautier, P ^a   Zagame L ^a   Taieb S ^b   Descamps, P ^c   Delaloge, S ^a   Morice, P ^a   Petrow, P ^a   Duvillard, P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Carcinomas; Endometrium; Follow up; Review; Tamoxifen

Indexed keywords

CA 125 ANTIGEN; CLOMIFENE; DIETHYLSTILBESTROL; ESTROGEN RECEPTOR; TAMOXIFEN;

CANCER RISK; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DOPPLER ECHOGRAPHY; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HYSTEROSCOPY; INCIDENCE; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK FACTOR; THICKNESS; TRANSVAGINAL ECHOGRAPHY; UTERINE CERVIX CYTOLOGY; UTERUS CARCINOMA; UTERUS DISEASE;

EID: 0042324281     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/S1297-9589(03)00195-4     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003 Jan 25;361(9354):296-300.
3. Deligdisch L, Kalir T, Cohen C, de Latour M, Le Bouedec G, Penaultllorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. GynOncol 2000;78:181-6.
4. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, Cailleux PE, Lhommé C. Five cases of uterine carcinosarcomas occuring under/after prolonged adjuvant tamoxifen. Int J Cancer Gynecol 2002;12:496-500.
5. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving anti-estrogens. Cancer Treat Report 1985;69:237-8.
6. Fornander T, Rutqvist LE, Cedemark B, Glas U, Mattsson A, Simfversward C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;2:117-20.
7. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995 May 3;87(9):645-51.
8. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
9. Menzin AW, Gal D. Should women receiving tamoxifen be screened for endometrial cancer? An argument for screening. Cancer Invest 2000;18:793-5.
10. Curtis RE, Boice JD, Shriner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Instit 1996;88:832-4.
11. Bernstein L, Deapen D, Cerhan J, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91: 1654-62.
12. Sasco AJ, Ah-Song R, Gendre I, et al. Cancer de l'endomètre et tamoxifène; discussion à partir d'une série de cas. Bull Cancer 1997;84:51-60.
13. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-receptor positive tumours. J Natl Cancer Inst 1996;88:1529-42.
14. Magriples U, Naftolin F, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
15. Fisher B, Costantino J, Wickerham L, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I study. J Natl Cancer Inst 1998;90:1371-88.
16. Descamps P, Cutuli B, Fondrinier E, Mignotte H, Classe JM, Neven P, Endometrial Carcinoma: Advances in endometrial cancer screening Elsevier Ed In Press. 2003.
17. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998 Nov 4;280(17):1510-7.
18. Koss LG, Schreiber K, Oberlander SG, Moussouris HF, Lesser M. Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 1984;64:1-11.
19. Barakat RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, Hoskins WJ. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000;20:3459-63.
20. Cecchini S, Ciatto S, Bonardi R, Mazotta A, Grazzini G, Pacini P, et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996;60:409-11.
21. Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999;17(7):2050-4.
22. Gerber B, Krause A, Muller H, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000;18(20):3464-70.
23. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994 May 28;343(8909):1318-21.
24. Goldstein S. Unusual ultrasonic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51.
25. McGonigle KF, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol 1998 Jun; 178(6):1145-50.
26. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol 1997;66:233-7.
27. Cohen I, Perel E, Flex D, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-82.
28. Taieb S, Ceugnart L, Chevalier A, Cabaret V, Leblanc E, Fournier C, Besson P. Apport de l'IRM chez les patientes symptomatiques traitées par tamoxifène. J Radiol 2003 Jan;84(1):33-9.
29. Berlière M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 1998;91:40-4.
30. Armeina CS. Sequential relationship between endometrial polyps and carcinoma of the endometrium. Obstet Gynecol 1967;30:524-9.
31. ACOG Committee. Opinion on tamoxifen and endometrial cancer N° 169. Feb. 1996.
32. e édition, mise à jour).
33. Barakat RR. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J Clin Oncol 1999 Jul;17(7):1967-8.
34. Runowicz CD. Gynecologic surveillance of women on tamoxifen: first do no harm. J Clin Oncol 2000;20:3457-8.
35. Suh-Burgmann EJ, Goodman A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann Intern Med 1999;131:127-35.
36. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002 Jun 1;20(11):2758-60.
37. International Breast Cancer Intervention Study (IBIS-1): First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002 Sep 14;360(9336):817-24.
38. Partridge EE, Singleton HM, Menck HR. The National Cancer Data Base report on endometrial cancer. J Surg Oncol 1996;61:111-23.
39. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer 1996;32:1464-76.
40. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001 May 15;19(10):2596-606.